Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics, Inc. (NASDAQ: OTLK) will release its third quarter earnings report before the opening bell on Friday, Aug. 14. Analysts expect the Iselin, New Jersey-based company to report a quarterly loss of 8 cents per share, versus a loss of 44 cents per share in the year-ago period. The consensus estimate for OTLK’s quarterly revenue is $966.67 thousand. It reported $1.5 million last year, according to Benzinga Pro.

On Aug. 12, Outlook Therapeutics announced the pricing of $55.0 million public offering of common stock and warrants. Shares of Outlook Therapeutics fell 19.2% to close at $0.89 on Thursday.